MPN Hub

At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Johannes Lübke, University Hospital Mannheim, Mannheim, DE, delivered a presentation on diagnosis, risk stratification, and response assessment in advanced systemic mastocytosis (AdvSM).  Lübke discusses the current diagnostic framework for systemic mastocytosis, emphasizing the need for integrated disease assessment beyond established diagnostic criteria. He explores the role of molecular profiling in prognostic risk stratification, evolving prognostic models in the era of KIT-targeted therapy, current and emerging approaches to response assessment, and the complementary role of patient-reported outcomes in evaluating disease burden and treatment benefit.This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

During the MPN Hub Steering Committee Meeting in May 2026, Andreas Reiter, University Hospital Mannheim, Mannheim, DE, delivered a presentation on targeting KIT in advanced systemic mastocytosis (AdvSM). In this presentation, Reiter discusses the rationale for KIT inhibition, and key efficacy and safety data for KIT-targeting therapies in AdvSM. The presentation highlights data from key trials, including the depth of molecular response with KIT-targeting therapies and its correlation with clinical benefit, and concludes with an overview of future directions in KIT inhibition for patients with AdvSM. This educational resource is independently supported by Blueprint Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. 

At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Andreas Reiter, University Hospital Mannheim, Mannheim, DE, delivered a presentation on clinical challenges and unmet needs in advanced systemic mastocytosis (AdvSM).  In this presentation, Reiter discusses how genetic complexity underpins disease heterogeneity and clinical presentation in AdvSM, how variable disease presentation can lead to diagnostic delays, and that treatment outcomes highlight variability across AdvSM subtypes. He explores the limitations of conventional disease burden assessment, the variable symptom burden impacts on quality of life across systemic mastocytosis (SM) subtypes, and how disease heterogeneity can lead to complexity in AdvSM management. In addition, he discusses the variability in morphology and genetics in SM with an associated hematologic neoplasm, and illustrates potential challenges in clinical practice using a patient case study. This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. 

At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Deepti H Radia, Guy's and St Thomas' NHS Foundation Trust, London, UK, delivered a presentation on disease biology and molecular architecture in advanced systemic mastocytosis (AdvSM).  In this presentation, Radia discusses the classification and biology of AdvSM, covering mast cell disease biology, the clinical and biological spectrum of AdvSM, KIT as a central molecular driver of AdvSM, additional somatic mutations, clonal architecture and disease evolution, and the mechanisms of disease progression and organ damage. This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. 

At the European School of Haematology (ESH) 11th Translational Research Conference: Myeloproliferative Neoplasms, Apr 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee Chair Jean-Jacques Kiladjian, Université Paris Cité - Hôpital Saint-Louis, Paris, FR, and Steering Committee members Steffen Koschmieder, Uniklinik RWTH Aachen, DE, and Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discussed future perspectives for cytopenic myelofibrosis (MF) during a panel discussion and Q&A session. In this presentation, Kiladjian, Koschmieder, and Harrison discuss practical approaches to the management of cytopenias in myelofibrosis, including treatment selection, management of treatment-emergent anemia, supportive care strategies, and future directions for individualized and combination therapies. This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. 

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigating therapeutic options for patients with cytopenic myelofibrosis. In this presentation, Koschmieder discusses current therapeutic approaches to cytopenic MF, including a review of key data on outcomes with momelotinib, pacritinib, luspatercept, and pelabresib and selinexor in combination with ruxolitinib.This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK, delivered a presentation on treatment options for patients with cytopenic myelofibrosis (MF), reviewing treatment algorithms and providing real‑world insights.In this presentation, Harrison discusses the impact of transfusions on patients with MF and MF subgroups, as well as the British Society for Haematology (BSH) 2024 and National Comprehensive Cancer Network (NCCN) 2026 guidelines for managing cytopenia in patients with MF. She also reviews real-world evidence for current treatment options, using patient cases to illustrate treatment selection in the clinical setting.This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of nuvisertib in combination with momelotinib in patients with relapsed/refractory myelofibrosis (R/R MF)?In this interview, Harrison discusses key findings from Arm 3 of the trial (NCT04176198), which enrolled patients who had been previously treated with a Janus kinase inhibitor (JAKi) other than momelotinib. The study aimed to identify the recommended phase II dose (RP2D) of nuvisertib when administered in combination with momelotinib, and to assess the safety, clinical activity (spleen volume reduction [SVR] and total symptom score [TSS] improvement), and pharmacokinetics and pharmacodynamic markers (including cytokines and bone marrow fibrosis).This educational resource is independently supported by Sumitomo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.